期刊文献+

坎地沙坦片治疗慢性心衰117例临床观察 被引量:2

The clinical observation of Candesartan Cilexetil Tablets treatment of chornic heart failure
下载PDF
导出
摘要 目的观察坎地沙坦片改善心力衰竭的疗效。方法慢性心力衰竭患者随机分为观察组60例与对照组57例,观察组采用坎地沙坦片治疗,对照组采用美托洛尔治疗;对比两组的NYHA疗效与Boston心衰计分评价。结果 NYHA心功能疗效观察组总有效率为96.7%,对照组86.0%;Boston心功能疗效观察组治疗组总有效率88.3%,对照组85.9%;组间比较两组疗效无显著性差异(P>0.05)。结论坎地沙坦片治疗慢性心力衰竭总体疗效趋势优于美托洛尔,两者疗效基本相当。 Objective To observe the treatment effect and safety of candesartan cilexetil tablets improving heart failure. Methods 117 cases of patients with heart failure were divided randomly into treatment group(60 cases) and control group( 57 cases).Treatment group was treated with Candesartan Cilexetil Tablets,while control group was treated with metoprolol tartrate tablets.The NYHA effect and Boston heart failure scoring effect of two groups were compared. Results As to the NYHA heart function effect,the total efficient rate of treatment group was 96.7% ,while that of control group was 86.0%.As to the Boston heart function effect,the total efficient rate of treatment group was 88.3% ,while that of control group was 85.9%.There was no significant difference in other observing indexes of two groups.Conclusion Candesartan cilexetil tablets and metoprolol tartrate tablets has the considerable treatment effect in improving heart failure.
机构地区 广州市老人院
出处 《中国实用医药》 2013年第1期38-39,共2页 China Practical Medicine
关键词 心力衰竭 坎地沙坦片 美托洛尔片 Heart failure Candesartan Cilexetil Tablets Metoprolol tartrate tablets
  • 相关文献

参考文献4

二级参考文献22

  • 1蔡德山.浅谈沙坦类抗高血压新药市场[J].中国制药信息,2007,23(4):29-32. 被引量:2
  • 2Johnston CL. Angiotensin receptor antagonists: focus on losartan [J]. Lancet,2000,346(8987):1403-1407.
  • 3Gleiter CH,Jagle C, Gresser U, et al. Candesartan Cardiovasc[J ] Drug Rev,2004,22(4):263-284.
  • 4Gleiter CH, Morike KE. Clinical pharmacokinetics of candesartan [J ]. Clinical Pharmacokinetics, 2002,41 ( 1 ) : 7 - 17.
  • 5Oparil S, Levine JH, Zuschke CA, et al. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators[J]. Am J Cardiol, 1999,84(3) :289 - 293.
  • 6Me Kelvie RS,Rouleau J, Latini R, et al. Comparison of candesartun, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigatotrs[J ]. Circulation, 1999,100(10) : 1056 - 1064.
  • 7Mitrovic V, Willenbrock R, Miric M, et al. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure[J]. Am Heart J ,2003,145(3) :E14.
  • 8Baguet JP,Barone-Rochette G, Neuder Y. Candesartan cilexetil in the treatment of chronic heart failure[J]. Vasc Health Risk Manag,2009,5(1):257-264.
  • 9Mitrovic V, Appel KF, Proskynitopoulos N, et al. Effects of candesartan cilexetil "add-on" treatment in congestive heart failure outpatients in daily practice[J ]. Clin Res Cardiol,2009,18.
  • 10Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and chronic angiotensin-lreoeptor antagonism reverses endothelial dysfunction in atherosclerosis[J]. Circulation,2000,101 (20) :2349 -2354.

共引文献1285

同被引文献22

  • 1刘力生.中国高血压防治指南2010[J].中国医学前沿杂志(电子版),2011,3(5):42-93. 被引量:1221
  • 2无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量:2065
  • 3Basi S, Lewis JB. Microalbuminuria as a target to improve cardio- vascular and renal outcomes [J]. Am J Kidney Dis,2006,47(6) : 927-946.
  • 4Cottone S, Mule G, Nardi E, et al. Mieroalbuminuria and early endothelial activation in essential hypertension [ J]. J Hum Hyper- tens, 2007 ,21 (2) :167-172.
  • 5Palmer AJ, Chen R, Valentine WJ, et al. Cost-consequence analysis in a Frech setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabets [ J ]. Diabetes Metab. 2006,32( 1 ) :69-76.
  • 6Gansevoort RT, De Jong PE. The case for using albuminuria in staging chronic kidney disease [ J ]. J Am Soc Nephrol, 2009,20 ( 3 ) :465-468.
  • 7Parving HH, Persson F, Julia B. Aliskiren combined with losartan in type 2 diabetes and nephropathy [ J ]. NEJM, 2012,358 ( 23 ) : 2433 -2446.
  • 8Erley CM, Haefele U, Heyne N,et al. Microalbuminuria in essen- tial hypertension. Reduction by different antihypertensive drugs [J]. Hypertension, 1993,21(6 Pt 1) :810-815.
  • 9Black HR,Graff A,Shute D,et al.Valsartan,a new angiotensin II antagonist for the treatment of essentialhypertension:efficacy,tolerability and safetycompared to an angiotensin-converting enzyme inhibitor,lisinopril [J].J Hum Hypertens,1997,11(8):483-489.
  • 10NAVIGATOR Study Group,McMurry JJ,Holman RR,et al.Effect of valsartan on the incidence of diabetes and cardiovascular events[J].N Engl J Med,2010,362(15):1477-1490.

引证文献2

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部